Abstract
Autologous stem cell transplantation (ASCT) is a new treatment option in patients with systemic AL amyloidosis (AL). The purpose of this review is to summarize the clinical experience of ASCT for AL, and to discuss the feasibility and the future developments of this new approach.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moreau, P. Autologous stem cell transplantation for AL amyloidosis: a standard therapy?. Leukemia 13, 1929–1931 (1999). https://doi.org/10.1038/sj.leu.2401593
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401593
Keywords
This article is cited by
-
Natural history and therapy of AL cardiac amyloidosis
Heart Failure Reviews (2015)
-
Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis
Bone Marrow Transplantation (2002)
-
Peripheral blood stem cell transplantation for POEMS syndrome
Bone Marrow Transplantation (2002)
-
Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation
Bone Marrow Transplantation (2001)
-
Biological features of the clone involved in primary amyloidosis (AL)
Leukemia (2001)